Current understanding and management of Parkinson disease: Five new things

Neurology

Volumn 75, Issue 18 SUPPL.1, 2010, Pages

  Morley, James F ^a   Hurtig, Howard I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BOTULINUM TOXIN; CARBIDOPA PLUS LEVODOPA; CEP 1347; CLONAZEPAM; CREATINE; DONEPEZIL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCOPYRRONIUM BROMIDE; LEVODOPA; MELATONIN; METHYLPHENIDATE; MIDODRINE; MINOCYCLINE; MODAFINIL; MONOAMINE OXIDASE B INHIBITOR; NEURTURIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMIGAPIL; PLACEBO; PRAMIPEXOLE; RASAGILINE; RILUZOLE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; THREO 3,4 DIHYDROXYPHENYLSERINE; TRICYCLIC ANTIDEPRESSANT AGENT; UBIDECARENONE; UNINDEXED DRUG;

ARTICLE; BRAIN DEPTH STIMULATION; CAUSAL ATTRIBUTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DEMENTIA; DEPRESSION; ENVIRONMENTAL FACTOR; ERECTILE DYSFUNCTION; FATIGUE; GENE MUTATION; GENETIC ASSOCIATION; HEREDITY; HUMAN; HYPERSALIVATION; INSOMNIA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; PERIODIC LIMB MOVEMENT DISORDER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; STEREOTAXIC SURGERY; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; URINALYSIS;

DEEP BRAIN STIMULATION; DISEASE MANAGEMENT; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 78650084465     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181fb3628     Document Type: Article

References (19)

1. Elbaz A, Grigoletto F, Baldereschi M, et al. Familial aggregation of Parkinson's disease: a population-based case-control study in Europe: EUROPARKINSON study group. Neurology 1999;52:1876-1882.
2. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009;41:1303-1307.
3. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009;41:1308-1312.
4. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
5. Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006;67:1786-1791.
6. Chade AR, Kasten M, Tanner CM. Nongenetic causes of Parkinson's disease. J Neural Transm Suppl 2006;70: 147-151.
7. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010; 16:79-84.
8. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010;67:798-801.
9. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
10. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:581-591.
11. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010;362:2077-2091.
12. Okun MS, Fernandez HH, Wu SS, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: The COMPARE trial. Ann Neurol 2009;65:586-595.
13. Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010;74: 995-1002.
14. Lohle M, Reichmann H. Clinical neuroprotection in Parkinson's disease: still waiting for the breakthrough. J Neu-rol Sci 2010;289:104-114.
15. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-1278.
16. Youdim MB. Rasagiline in Parkinson's disease. N Engl J Med 2010;362:657-658; author reply 658-659.
17. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24:1641-1649.
18. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney Multicenter Study of Parkinson's Disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
19. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: Treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74: 924-931.